ArticleScientific reports2026
Synergistic Effects of Laser-synthesized Silver Nanoparticles and Photosensitizers for enhanced Antibacterial and Anticancer activity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synergistic use of silver nanoparticles (AgNPs) and photosensitizer's offers promise biomedical improvements. This study assesses and creates the potential for photosensitizers (Chlorine e6 (Ce6), Methylene Blue (MB)) and Silver Nanoparticles to work together to enhance biological activity. AgNPs were created by the laser ablation method and characterized using methods including scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy, and X-ray diffraction (XRD).The antibacterial and anticancer properties of these nanoparticles, both individually and in combination with photosensitizers, were further examined. AgNPs were combined with Methylene Blue and Chlorine e6 to enhance their antibacterial activity against Gram-negative bacteria, such as Salmonella enteritidis, Pseudomonas aeruginosa, and Acinetobacter baumannii, resulting in inhibition zones of up to as large as 0.66 ± 057 mm. The anticancer properties of the combination therapy were also examined against MCF-7 breast cancer cells, where Chlorine e6 alone had an IC50 of approximately 231.2%. Another photosensitizer, Methylene blue, showed a dose-dependent reduction in cell viability, with an IC50 of around 6.52 ± 3.26%. When AgNPs and Methylene Blue combined, the IC50 decreased to 11.42 ± 5.71, indicating a synergistic increase in cytotoxicity. Similarly, Chlorine e6 and AgNPs together significantly decreased the IC50 to 80µM to 100 µM. These findings show that the combined use of Methylene Blue or Chlorine e6 with AgNPs greatly improves anticancer and antibacterial efficacy compared to their individual applications. This research highlights how AgNPs and photosensitizers have the ability to change treatment approaches by providing improved specificity and efficacy in biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.